top of page

KiraGen Advances to Semi-Finals of HBS Shark Tank for Chance to Pitch Kevin O'Leary

Navigating the vibrant and diverse ecosystem of the Harvard Business School Shark Tank competition, KiraGen Bio is proud to have secured a place in the semi-finals, distinguishing ourselves in a field often dominated by sectors such as consumer goods, tech, and real estate. Our advancement is noteworthy, reflecting not just the potential of our AI-driven CAR-T cell therapies but also the significance of biotechnology in an entrepreneurial landscape rich with varied industries. This achievement speaks volumes about the resonance of our vision to innovate cancer treatment and the dedication of our team to make a meaningful impact in a complex and crucial field of healthcare. It's a commendable milestone for KiraGen Bio, emphasizing the growing importance and recognition of biotech in the broader tapestry of business innovation.


bottom of page